Initial term of Pharmaceutical Sourcing Venture

No definition available.

Name:	cah_InitialtermofPharmaceuticalSourcingVenture
Namespace Prefix:	cah_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.

+ References

No definition available.

+ Details

Name:	cah_MaximumQuarterlyPayment
Namespace Prefix:	cah_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LitigationReserve
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=cah_DEAInvestigationandRelatedMattersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=cah_CVSHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments, Contingent Liabilities and Litigation (Details) $ in Millions		1 Months Ended	3 Months Ended
	Oct. 31, 2016 plaintiff lawsuit	Jul. 31, 2014	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)
Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed \| lawsuit	31
Number of plaintiffs \| plaintiff	250
DEA Investigation and Related Matters
Loss Contingencies [Line Items]
Litigation accrual			$ 44.0	$ 44.0
CVS Health
Loss Contingencies [Line Items]
Initial term of pharmaceutical sourcing venture		10 years
Maximum quarterly payment			$ 45.6